Literature DB >> 6834081

Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression.

O R Hommes, F Aerts, U Bahr, H R Schulten.   

Abstract

The cyclophosphamide content of urine, serum and spinal fluid of immuno-suppressed multiple sclerosis patients was determined using a newly developed off-line combination of high pressure liquid chromatography and field desorption mass spectrometry. Although urinary excretion of the drug varied considerably between patients, the levels in serum and spinal fluid were in the same range, a relationship that may facilitate control of the dosage.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834081     DOI: 10.1016/0022-510x(83)90224-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

Review 1.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.

Authors:  Daniel M Harrison; Douglas E Gladstone; Edward Hammond; Jeffrey Cheng; Richard J Jones; Robert A Brodsky; Douglas Kerr; Justin C McArthur; Adam Kaplin
Journal:  Mult Scler       Date:  2011-08-24       Impact factor: 6.312

Review 3.  Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Authors:  James M Stankiewicz; Hadar Kolb; Arnon Karni; Howard L Weiner
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 4.  High-dose chemotherapy and multiple sclerosis.

Authors:  Daniel Harrison; Douglas E Gladstone
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

6.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15

Review 7.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08

8.  Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue.

Authors:  Valeria Koska; Moritz Förster; Katja Brouzou; Maryam Hatami; Ercan Arat; Ahmet Aytulun; Philipp Albrecht; Orhan Aktas; Patrick Küry; Sven G Meuth; David Kremer
Journal:  Front Neurol       Date:  2021-06-23       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.